Tenderwize
Retour à la recherche

Non-exclusive discount agreement for Nadroparin

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Oct 27, 2026 · 67 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Nadroparin (ATC-Code: B01AB06).

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

Open-house contracts terminate automatically when exclusive discount contracts take effect, which may happen 6-8 months...

Since the agreement is non-exclusive and open to all, there is no minimum purchase commitment from the buyer.

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Supply of Nadroparin (ATC B01AB06) under a non-exclusive discount agreement
  • Open-house model with uniform conditions for all participants
Afficher le résumé complet

This is a non-exclusive discount agreement (open-house model) for pharmaceutical products containing Nadroparin (ATC B01AB06) offered by AOK Niedersachsen. It is a bridge between patent expiry and exclusive contracts. Any pharmaceutical entrepreneur meeting eligibility can join at any time from 2025-01-01 to 2026-12-31. The first entry deadline is 2024-11-27. The contract is not a public procurement; it uses a transparency publication.

Risques

Open-house contracts terminate automatically when exclusive discount contracts take effect, which may happen 6-8 months...

Since the agreement is non-exclusive and open to all, there is no minimum purchase commitment from the buyer.

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG
  • Must have seat in EU/EEA or Germany
  • Only the active ingredient Nadroparin (ATC B01AB06) is covered

Critères d'attribution

Lot 1

Price - no further details

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Non-exclusive discount agreement for Nadroparin

Open-house model for Nadroparin (ATC B01AB06) from 2025-01-01 to 2026-12-31. All pharmaceutical companies may join under uniform conditions. Contracts end automatically when exclusive contracts come into effect. The first sign-up deadline is 2024-11-27; later entry possible monthly with 35-day advance notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Dec 2024 - Dec 2026

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Expired Nov 27, 2024

Détails de la procédure

Date de publication
04 Nov 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
671589-2024

Appels d'offres similaires